betamethasone valerate

ApprovedSmall molecule

GSK

betamethasone valerate is one of 119 small molecule programs targeting Atopic Eczema. It is currently in Approved.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic EczemaActive, not recruiting

Psoriasis VulgarisActive, not recruiting

Contact DermatitisActive, not recruiting

RadiodermatitisActive, not recruiting

PsoriasisActive, not recruiting

ParonychiaActive, not recruiting

Atopic EczemaPhase 3

Active, not recruiting

Psoriasis VulgarisApproved

Active, not recruiting

Contact DermatitisPhase 2/Phase 3

Active, not recruiting

RadiodermatitisApproved

Active, not recruiting

PsoriasisPhase 1

Active, not recruiting

ParonychiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

betamethasone valerate

GSK

Approved

2 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Recruiting

Contact Dermatitis

NCT05535738

Clinical

Trials by Indication[1]

Psoriasis2 trials

Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

Completed· GSK logo

GSK·Phase 1·NCT00358384·10 enrolled

SHP-141C in Plaque Type Psoriasis

Completed·TTetraLogic Pharmaceuticals·Phase 1·NCT01646567·14 enrolled

Recurrence1 trial

A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema

Completed·AACO Hud Nordic AB·Phase 4·NCT00576550·53 enrolled

Paronychia1 trial

Efficacy and Safety of Timolol for TKI Induced Paronychia

Unknown status·QQueen Mary Hospital, Hong Kong·Phase 3·NCT06140186·40 enrolled

Psoriasis Vulgaris1 trial

Excimer Laser With Topical Agents in Psoriasis Vulgaris

Unknown status·—·Phase 4·NCT05555797·30 enrolled

Atopic Eczema1 trial

Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser

Completed·AACO Hud Nordic AB·Phase 3·NCT00576238·55 enrolled

3 more indications

Contact Dermatitis1 trial

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Recruiting·WWei-Che Ko·Phase 2/3·NCT05535738·45 enrolled

Radiodermatitis1 trial

Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients

Completed·—·Phase 4·NCT05285943·132 enrolled

Age1 trial

Comparative Effect of Nigella Sativa and Conventional Management for OSMF

Completed·ZZiauddin University·Phase 3·NCT04476420·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for betamethasone valerate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — betamethasone valerate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for betamethasone valerate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

betamethasone valerate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Psoriasis2 trials

Recurrence1 trial

Paronychia1 trial

Psoriasis Vulgaris1 trial

Atopic Eczema1 trial

Contact Dermatitis1 trial

Radiodermatitis1 trial

Age1 trial

References

Drug Info

Quick Facts

Related News